Bill Status of HB 1443   104th General Assembly

Short Description:  HEALTH CARE AVAILABILITY

House Sponsors
Rep. Nabeela Syed, Katie Stuart, Diane Blair-Sherlock, Janet Yang Rohr, Theresa Mah, Abdelnasser Rashid, Mary Beth Canty, Kelly M. Cassidy, Will Guzzardi, Michelle Mussman, Nicolle Grasse, Norma Hernandez, Kevin John Olickal, Gregg Johnson, Camille Y. Lilly, Suzanne M. Ness, Debbie Meyers-Martin, Anne Stava-Murray, Anna Moeller, Maura Hirschauer, Dagmara Avelar, La Shawn K. Ford and Joyce Mason

Last Action  View All Actions

DateChamber Action
  3/21/2025HouseRule 19(a) / Re-referred to Rules Committee

Statutes Amended In Order of Appearance
New Act
30 ILCS 105/5.1030 new

Synopsis As Introduced
Creates the Health Care Availability and Access Board Act. Establishes the Health Care Availability and Access Board to protect State residents, State and local governments, commercial health plans, health care providers, pharmacies licensed in the State, and other stakeholders within the health care system from the high costs of prescription drug products. Contains provisions concerning Board membership and terms; staff for the Board; Board meetings; circumstances under which Board members must recuse themselves; and other matters. Provides that the Board shall perform the following actions in open session: (i) deliberations on whether to subject a prescription drug product to a cost review; and (ii) any vote on whether to impose an upper payment limit on purchases, payments, and payor reimbursements of prescription drug products in the State. Permits the Board to adopt rules to implement the Act and to enter into a contract with a qualified, independent third party for any service necessary to carry out the powers and duties of the Board. Creates the Health Care Availability and Access Stakeholder Council to provide stakeholder input to assist the Board in making decisions as required by the Act. Contains provisions concerning Council membership, member terms, and other matters. Provides that the Board shall adopt the federal Medicare Maximum Fair Price as the upper payment limit for a prescription drug product intended for use by individuals in the State. Prohibits the Board from creating an upper payment limit that is different from the Medicare Maximum Fair Price for the prescription drug product that has a Medicare Maximum Fair Price. Requires the Board to implement an upper payment limit that is the same as the Medicare Maximum Fair Price no sooner than the Medicare implementation date. Provides that Medicare Part C and D plans are not required to reimburse at the upper payment limit. Provides that the Attorney General may enforce the Act and may pursue any available remedy under State law when enforcing the Act. Effective 180 days after becoming law.

Actions 
DateChamber Action
  1/17/2025HouseFiled with the Clerk by Rep. Nabeela Syed
  1/28/2025HouseFirst Reading
  1/28/2025HouseReferred to Rules Committee
  2/3/2025HouseAdded Co-Sponsor Rep. Katie Stuart
  2/4/2025HouseAdded Co-Sponsor Rep. Diane Blair-Sherlock
  2/4/2025HouseAdded Co-Sponsor Rep. Janet Yang Rohr
  2/11/2025HouseAdded Co-Sponsor Rep. Theresa Mah
  2/13/2025HouseAdded Co-Sponsor Rep. Abdelnasser Rashid
  2/13/2025HouseAdded Co-Sponsor Rep. Mary Beth Canty
  2/18/2025HouseAdded Co-Sponsor Rep. Kelly M. Cassidy
  2/18/2025HouseAssigned to Health Care Availability & Accessibility Committee
  2/18/2025HouseAdded Co-Sponsor Rep. Will Guzzardi
  2/19/2025HouseAdded Co-Sponsor Rep. Michelle Mussman
  2/19/2025HouseAdded Co-Sponsor Rep. Nicolle Grasse
  2/25/2025HouseAdded Co-Sponsor Rep. Norma Hernandez
  2/25/2025HouseAdded Co-Sponsor Rep. Kevin John Olickal
  2/25/2025HouseAdded Co-Sponsor Rep. Gregg Johnson
  2/25/2025HouseTo Prescription Drug Affordability Board
  2/26/2025HouseAdded Co-Sponsor Rep. Camille Y. Lilly
  2/26/2025HouseAdded Co-Sponsor Rep. Suzanne M. Ness
  3/4/2025HouseAdded Co-Sponsor Rep. Debbie Meyers-Martin
  3/5/2025HouseAdded Co-Sponsor Rep. Anne Stava-Murray
  3/7/2025HouseAdded Co-Sponsor Rep. Anna Moeller
  3/13/2025HouseAdded Co-Sponsor Rep. Maura Hirschauer
  3/13/2025HouseAdded Co-Sponsor Rep. Dagmara Avelar
  3/21/2025HouseRule 19(a) / Re-referred to Rules Committee
  4/29/2025HouseAdded Co-Sponsor Rep. La Shawn K. Ford
  5/14/2025HouseAdded Co-Sponsor Rep. Joyce Mason

Back To Top